Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder

References

• McClernon FJ, Kollins SH. ADHD and smoking: from genes to brain to behavior. Ann N Y Acad Sci. 2008;1141:131–47. doi:10.1196/annals.1441.016.
   PubMed Web of Science ®Google Scholar
• Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 1995;7(3):373–78. doi:10.1016/0899-3289(95)90030-6.
   PubMedGoogle Scholar
• Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62(10):1142–47. doi:10.1001/archpsyc.62.10.1142.
   PubMed Web of Science ®Google Scholar
• Tercyak KP, Lerman C, Audrain J. Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41(7):799–805. doi:10.1097/00004583-200207000-00011.
   PubMed Web of Science ®Google Scholar
• Whalen CK, Jamner LD, Henker B, Delfino RJ, Lozano JM. The ADHD spectrum and everyday life: experience sampling of adolescent moods, activities, smoking, and drinking. Child Dev. 2002;73(1):209–27. doi:10.1111/1467-8624.00401.
   PubMed Web of Science ®Google Scholar
• Levin ED, Conners CK, Silva D, Canu W, March J. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2001;9(1):83–90.
   PubMed Web of Science ®Google Scholar
• Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996;123(1):55–63. doi:10.1007/BF02246281.
   PubMed Web of Science ®Google Scholar
• Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857–64. doi:10.1001/archpedi.161.9.857.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(Suppl 1):S31–43. doi:10.1177/070674370200601S05.
   PubMedGoogle Scholar
• Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68(5):2032–37. doi:10.1046/j.1471-4159.1997.68052032.x.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010;30(5):549–53. doi:10.1097/JCP.0b013e3181ee84a7.
   PubMed Web of Science ®Google Scholar
• Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(12):1680–88. doi:10.4088/JCP.09m05089gry.
   PubMed Web of Science ®Google Scholar
• Covey LS, Hu MC, Winhusen T, Weissman J, Berlin I, Nunes EV. OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences. Drug Alcohol Depend. 2010;110(1–2):156–59. doi:10.1016/j.drugalcdep.2010.02.002.
   PubMed Web of Science ®Google Scholar
• Heffner JL, Lewis DF, Winhusen TM. Preliminary evidence that adherence to counseling mediates the effects of pretreatment self-efficacy and motivation on outcome of a cessation attempt in smokers with ADHD. Nicotine Tob Res. 2013;15(2):393–400. doi:10.1093/ntr/nts135.
   PubMed Web of Science ®Google Scholar
• Westover AN, Kashner TM, Winhusen TM, Golden RM, Nakonezny PA, Adinoff B, Henley SS. A systematic approach to subgroup analyses in a smoking cessation trial. Am J Drug Alcohol Abuse. 2015;41(6):498–507. doi:10.3109/00952990.2015.1044605.
   PubMed Web of Science ®Google Scholar
• Covey LS, Hu MC, Weissman J, Croghan I, Adler L, Winhusen T. Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate. Nicotine Tob Res. 2011;13(10):1003–08. doi:10.1093/ntr/ntr087.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Covey LS, Brigham G, Hu MC, Levin FR, Somoza EC, Winhusen TM. Treating nicotine dependence by targeting attention-deficit/hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response. J Clin Psychiatry. 2013;74(10):983–90. doi:10.4088/JCP.12m08155.
   PubMed Web of Science ®Google Scholar
• Luo SX, Covey LS, Hu MC, Levin FR, Nunes EV, Winhusen TM. Toward personalized smoking-cessation treatment: using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers. Am J Addict. 2015 June;24(4):348–56. doi:10.1111/ajad.12193.
   PubMed Web of Science ®Google Scholar
• Piper ME, Federmen EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, Baker TB. Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol. 2008;117(1):94–105. doi:10.1037/0021-843X.117.1.94.
   PubMed Web of Science ®Google Scholar
• Bolt DM, Piper ME, Theobald WE, Baker TB. Why two smoking cessation agents work better than one: role of craving suppression. J Consult Clin Psychol. 2012;80(1):54–65. doi:10.1037/a0026366.
   PubMed Web of Science ®Google Scholar
• Berlin I, Hu MC, Covey LS, Winhusen T. Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD. Drug Alcohol Depend. 2012;124(3):268–73. doi:10.1016/j.drugalcdep.2012.01.019.
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: Guilford Press; 1998.
   Google Scholar
• Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187–201. doi:10.1016/j.psc.2003.12.003.
   PubMed Web of Science ®Google Scholar
• Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289–94. doi:10.1001/archpsyc.1986.01800030107013.
   PubMed Web of Science ®Google Scholar
• Vansickel AR, Stoops WW, Glaser PE, Poole MM, Rush CR. Methylphenidate increases cigarette smoking in participants with ADHD. Psychopharmacology (Berl). 2011;218(2):381–90. doi:10.1007/s00213-011-2328-y.
   PubMed Web of Science ®Google Scholar
• Rush CR, Higgins ST, Vansickel AR, Stoops WW, Lile JA, Glaser PE. Methylphenidate increases cigarette smoking. Psychopharmacology (Berl). 2005;181(4):781–89. doi:10.1007/s00213-005-0021-8.
   PubMed Web of Science ®Google Scholar
• Tidey JW, O’Neill SC, Higgins ST. d-amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology (Berl). 2000;153(1):85–92. doi:10.1007/s002130000600.
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Tidey JW, Badger GJ, Higgins ST. Acute effects of D-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology (Berl). 2003;167(4):393–402. doi:10.1007/s00213-003-1416-z.
   PubMed Web of Science ®Google Scholar
• Magee JC, Lewis DF, Winhusen T. Evaluating nicotine craving, withdrawal, and substance use as mediators of smoking cessation in cocaine- and methamphetamine-dependent patients. Nicotine Tob Res. 2016;18(5):1196–201. doi:10.1093/ntr/ntv121.
   PubMed Web of Science ®Google Scholar
• West R, Ussher M. Is the ten-item Questionnaire of Smoking Urges (QSU-brief) more sensitive to abstinence than shorter craving measures? Psychopharmacology (Berl). 2010;208(3):427–32. doi:10.1007/s00213-009-1742-x.
   PubMed Web of Science ®Google Scholar
• MacKinnon DP, Luecken LJ. How and for whom? Mediation and moderation in health psychology. Health Psychol. 2008;27(2S):S99–S100. doi:10.1037/0278-6133.27.2(Suppl.).S99.
   PubMedGoogle Scholar